CA
NZ
UK
AU
IND
US
SpyGlass Pharma posted a net loss of $19.9 million, or $0.59 per share, for the quarter ended June 30, a sharp increase from the $8.7 million loss a year earlier. Earnings per share came in at $‑0.69 versus a consensus estimate of $‑0.51, underscoring …
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) affirmed its strategy for expedited regulatory review of its investigational WEE1 inhibitor, azenosertib, following productive discussions with the U.S. regulatory agency. The company disclosed its financial performance for the second quarter concluded June 30, 2026, along with updates on …
Xenon Pharmaceuticals incurred a net loss of $110.7 million in Q2, with an EPS of $-1.11, outperforming the $-1.16 consensus estimate. This positive earnings surprise, combined with $1.2 billion in cash equivalents, positions the company well for continued investment in clinical trials and drug …
Sarepta Therapeutics has refined its product revenue forecast for 2026, now projected between $1.2 billion and $1.3 billion, indicating a shift toward the lower end of previous estimates. The company cited delays in treatment enrollment as a key factor affecting this guidance, especially in …
Solid Biosciences announced that it has amended its shelf registration statement to allow the issuance of common stock representing a total value of up to $200.0 million. This expansion adds capacity beyond the prior authorization, which permitted a maximum aggregate offering price of $85.0 …
The profit surge reflects a combination of $5.0 million collaboration and license revenue and a $39.2 million gain on the fair‑value change of its 2025 PIPE tranche liability. Investors see the earnings lift as a sign that the company’s pipeline and partnership strategy are …
The company also kicked off its first Phase 3 OCEAN‑1 trial in idiopathic pulmonary fibrosis‑related chronic cough and a Phase 2b LAKE trial for refractory chronic cough, underscoring an aggressive development agenda.
This marked an increase of 18.7% compared to the prior quarter and reflects a strong demand for its YCANTH product, primarily used for treating dermatological conditions. Shares of Verrica are currently facing challenges, down 35.4% year-to-date and 19% over the past month, suggesting that …
Valion Bio (NASDAQ: VBIO) announced a revised licensing framework that expands its payment capacity to an aggregate $5.6 million and obligates a $750,000 milestone tied to inventory validation. By widening the cash flow ceiling, the firm hopes to fund development of its Toll‑like Receptor …
VTv Therapeutics Inc. (NASDAQ: VTVT) delivered a striking $1.94 earnings per share for the quarter ended June 30 2026, eclipsing the $‑0.10 consensus projection. The biotech's cash balance stands at $86.6 million, enough to finance operations through the anticipated readout of its Phase 3 …
Please wait processing your request...